SubHero Banner

Xpovio (selinexor) – New orphan drug approval

July 3, 2019 - The FDA announced the approval of Karyopharm’s Xpovio (selinexor), in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Download PDF